High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer

Bone Marrow Transplantation

Volumn 20, Issue 3, 1997, Pages 199-203

  Viens, P ^a   Gravis, G ^a   Genre, D ^a   Bertucci, F ^a   Cowen, D ^a   Camerlo, J ^a   Cappiello, M A ^a   Conte, M ^a   Finaud, M ^a   Chabannon, C ^a   Houvenaeghel, G ^a   Maraninchi, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Breast cancer; Chemotherapy; Stem cells

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; APHERESIS; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; NEUTROPHIL; PRIORITY JOURNAL; STEM CELL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0030739812     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700870     Document Type: Article

References (24)

1. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
2. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-1170.
3. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. New Engl J Med 1981; 304: 10-15.
4. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New Engl J Med 1994; 330: 1253-1259.
5. Jones RB, Holland JF, Bhardwaj S et al. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 1987; 5: 172-177.
6. Frei E III, Teicher BA, Holden SA et al. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417-6423.
7. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New Engl J Med 1988; 318: 1414-1422.
8. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-324.
9. Sternberg CN, de Mulder PHM, van Oosterom AT et al. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol 1993; 4: 403-407.
10. Chevallier B, Chollet P, Merrouche Y et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564-1571.
11. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
12. Pettengell R, Woll PJ, Thatcher N et al. Multicyclic, doseintensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13: 148-156.
13. Shea TC, Mason JR, Storniolo AM et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992; 10: 464-473.
14. Tepler I, Cannistra SA, Frei E III et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993; 11: 1583-1591.
15. Patrone F, Ballestrero A, Ferrando F et al. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 1995; 13: 840-846.
16. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496.
17. Scinto AF, Ferraresi V, Campioni N et al. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer. Ann Oncol 1995; 6: 665-671.
18. Honkoop AH, Hoekman K, Wagstaff J et al. Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Ann Oncol 1996; 7: 35-39.
19. Shipp MA, Neuberg D, Janicek M et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995; 13: 2916-2923.
20. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
21. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncal 1992; 10: 1743-1774.
22. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
23. Vahdat L, Raptis G, Fennelly D et al. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res 1995; 1: 1267-1273.
24. Piccart MJ, Bruning P, Wildiers J et al. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. Ann Oncol 1995; 6: 673-677.